- ►annals.org [PDF] HM Kantarjian, M Talpaz, F Giles, S O'Brien, J … - Annals of internal medicine, 2006 - Am Coll Physicians Chronic myeloid leukemia (CML) was the first human malignant disease to be
linked to a single, acquired genetic abnormality. Identification of the BCR-ABL
kinase fusion protein and its central role in the pathogenesis of CML ... Cited by 85 - Related articles - BL Direct - All 3 versions
POFCM LEUKEMIA - Ann Intern Med, 2006 - info.medicine.ufl.edu Chronic myeloid leukemia (CML) was the first human malignant disease to be
linked to a single, acquired genetic abnormality. Identification of the BCR-ABL
kinase fusion protein and its central role in the pathogenesis of CML ... Cited by 1 - Related articles - View as HTML - All 2 versions
- ►ascopubs.org NP Shah, HM Kantarjian, DW Kim, D Rea, PE … - Journal of Clinical Oncology, 2008 - jco.ascopubs.org Purpose Dasatinib is a BCR-ABL inhibitor, 325-fold more potent than imatinib
against unmutated BCR-ABL in vitro. Phase II studies have demonstrated efficacy
and safety with dasatinib 70 mg twice daily in chronic-phase (CP) chronic ... Cited by 57 - Related articles - All 5 versions
H Kantarjian, S O'Brien, J Shan, X Huang, G … - CA A Cancer Journal for Clinicians - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 21 - Related articles - BL Direct - All 2 versions
- ►hematologylibrary.org - Free from Publisher A Quintas-Cardama, H Kantarjian, D Jones, C … - Blood, 2007 - bloodjournal.hematologylibrary.org Developing strategies to counteract imatinib resistance constitutes a challenge
in chronic myelogenous leukemia (CML). Therapy with the tyrosine kinase
inhibitors nilotinib (AMN107) and dasatinib (BMS-354825) has produced high ... Cited by 78 - Related articles - All 7 versions
[CITATION] Efficacy of nilotinib (formerly AMN107) in patients (pts) with newly diagnosed, previously …
J Cortes, SO'Brien, D Jones, A Ferrajoli, M … - Blood (ASH Annu Meet Abstracts), 2008 Cited by 18 - Related articles
R Larson, O Ottman, H Kantarjian, P le Coutre … - Journal of Clinical Oncology, 2007 - Am Soc Clin Oncol Background: Nilotinib is a highly selective Bcr-Abl tyrosine kinase inhibitor
that is 30-fold more potent than imatinib. In a phase I trial, nilotinib
demonstrated efficacy and favorable tolerability in these pts. These ... Cited by 18 - Related articles - All 2 versions
- ►hematologylibrary.org HM Kantarjian, F Giles, N Gattermann, K … - Blood, 2007 - bloodjournal.hematologylibrary.org Nilotinib, an orally bioavailable, selective Bcr-Abl tyrosine kinase inhibitor,
is 30-fold more potent than imatinib in pre-clinical models, and overcomes most
imatinib resistant BCR-ABL mutations. In this phase 2 open-label study, 400 ... Cited by 153 - Related articles - BL Direct - All 6 versions
[CITATION] Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia …
G Saglio, H Dombret, D Rea… - 13th Annual Congress of the European Hematology …, 2008 Cited by 10 - Related articles
[CITATION] Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia …
D Rea, H Dombret, DW Kim… - 13th Annual Congress of the European Hematology …, 2008 Cited by 10 - Related articles
